海创药业(688302) - 2025 Q1 - 季度财报

Financial Performance - The net profit attributable to shareholders of the listed company for the first quarter was -32,101,768.77 RMB, an improvement from -47,214,827.41 RMB in the same period last year, representing a decrease of 32.1%[5] - The basic earnings per share for the first quarter was -0.32 RMB, an improvement from -0.48 RMB in the same period last year[5] - The weighted average return on net assets was -2.73%, an improvement from -3.51% in the previous year[5] - Net loss for Q1 2025 was CNY 32.10 million, compared to a net loss of CNY 47.21 million in Q1 2024, representing an improvement of about 32.06%[20] - The company reported a total comprehensive loss of CNY 32.11 million in Q1 2025, compared to a loss of CNY 47.19 million in Q1 2024, indicating a 32.00% improvement[20] Cash Flow - The net cash flow from operating activities was -35,254,906.06 RMB, compared to -60,666,610.51 RMB in the previous year, indicating a 41.9% improvement[5] - Cash flow from operating activities showed a net outflow of CNY 35.25 million in Q1 2025, compared to a net outflow of CNY 60.67 million in Q1 2024, indicating a 41.83% improvement[22] - Cash inflow from investment activities decreased from CNY 773.84 million in Q1 2024 to CNY 373.87 million in Q1 2025, a decline of approximately 51.68%[22] - Net cash flow from investing activities was negative at approximately -$379.49 million, compared to -$468.04 million previously[23] - Cash flow from financing activities resulted in a net outflow of approximately -$1.22 million, worsening from -$805.11 thousand in the prior period[23] - The net increase in cash and cash equivalents was approximately -$416.11 million, compared to -$529.40 million in the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were 1,309,872,661.73 RMB, a decrease of 3.80% from 1,361,579,788.43 RMB at the end of the previous year[6] - The equity attributable to shareholders of the listed company was 1,163,678,573.11 RMB, down 2.40% from 1,192,245,114.75 RMB at the end of the previous year[6] - Total liabilities decreased from CNY 169.33 billion in Q1 2024 to CNY 146.19 billion in Q1 2025, a reduction of approximately 13.66%[17] - Total equity attributable to shareholders decreased from CNY 1.19 billion in Q1 2024 to CNY 1.16 billion in Q1 2025, a decline of about 2.67%[17] Research and Development - Total R&D investment amounted to 24,765,858.75 RMB, down 41.0% from 41,975,598.89 RMB year-on-year[5][9] - Research and development expenses decreased from CNY 41.98 million in Q1 2024 to CNY 24.77 million in Q1 2025, a reduction of approximately 41.00%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,193[11] - The largest shareholder, AFFINITIS GROUP LLC, held 13,125,294 shares, accounting for 13.26% of the total shares[11] Other Financial Metrics - Non-recurring gains and losses totaled 5,358,885.73 RMB for the period[8] - The company's cash and cash equivalents decreased significantly to RMB 201,109,921.11 from RMB 633,443,935.77, representing a decline of about 68.3%[15] - The total current assets increased to RMB 934,096,922.92 from RMB 885,541,034.62, marking an increase of approximately 5.5%[15] - The company's inventory rose sharply to RMB 935,654.36 from RMB 4,557.13, indicating a significant increase[15] - Non-current assets decreased to RMB 375,775,738.81 from RMB 476,038,753.81, a decline of about 21.1%[16] - The company's short-term borrowings remained at zero, indicating no reliance on short-term debt[16] - Accounts payable decreased to RMB 90,266,923.75 from RMB 96,869,887.98, a reduction of approximately 6.0%[16] - The company reported a significant increase in employee compensation payable, rising to RMB 7,588,330.83 from RMB 5,862,712.77, an increase of about 29.4%[16] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[23]